<DOC>
	<DOCNO>NCT02336945</DOCNO>
	<brief_summary>This multi-center , prospective , non-pivotal , single arm , non-significant risk evaluation Abbott Sensor Based Glucose Monitoring System - Pro across different stage T2 diabetes management . This non-significant risk study .</brief_summary>
	<brief_title>Glucose Variability Pilot Study Abbott Sensor Based Glucose Monitoring System-Professional</brief_title>
	<detailed_description>Subjects wear two Sensors , one apply back upper arm , period 14 day . Subjects wear Sensor go normal daily activity home use period . Subjects able see glucose data . The device remove completion final study visit . Data obtain Reader report generate system use subject research team member determine treatment . Subjects must adhere diabetes clinical management plan establish prior study . No additional medical care provide study subject follow study completion care relate follow treatment adverse event .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Subject must least 18 year age . 2 . Subject must diagnosis type 2 diabetes prior enrollment . 3 . Subject must current treatment regimen least 6 month prior enrollment must remain therapy regimen duration study ( subject diagnose within last 6 month must medication prior throughout study enroll ) . 4 . HbA1c great equal 6.0 % less equal 12.0 % demonstrate lab HbA1c result obtain within last 6 month . 1 . Subjects HbA1c &lt; 7.5 % exclude study subject 's intended therapy group enrollment require HbA1c ≥7.5 % . 2 . For therapy group enrol 12 subject HbA1c &lt; 7.5 % 12 subject HbA1c ≥7.5 % , subject HbA1c level within respective range exclude study enrollment goal HbA1c range meet . 3 . If HbA1c take within last six month available , new laboratory HbA1c value must obtain prior Sensor application . 5 . Subject must able read understand English . 6 . In investigator 's opinion , subject must able follow instruction provide him/her study site perform study task specify protocol 7 . In investigator opinion , subject must compliant diabetes management plan must able adhere medication regimen throughout study . 8 . Subject must available participate study visit . 9 . Subject must willing able provide write sign date informed consent . 1 . Subject know allergy medical grade adhesive isopropyl alcohol use disinfect skin . 2 . Subject pregnant , attempt conceive willing able practice birth control study duration ( applicable female subject ) . 3 . Subject skin lesion , scar , redness , infection edema application site could interfere device placement accuracy interstitial glucose measurement . 4 . Subject currently participate another clinical trial . 5 . Subject Xray , MRI CT appointment schedule period study participation , appointment reschedule time study participation start study participation end . 6 . HbA1c le 6.0 % great 12.0 % demonstrate lab HbA1c result obtain within last 6 month . 7 . Enrollment goal Subject 's intended therapy group meet . 8 . Subject unsuitable participation due cause determine Investigator . 9 . Subject currently one follow treatment treatment combination : 1 . Metformin + Sulfonylurea + DPP4 Inhibitor 2 . Sulfonylurea + DPP4 Inhibitor 3 . Metformin + Sulfonylurea + GLP1 Receptor Agonist 4 . Sulfonylurea + GLP1 Receptor Agonist 5 . Metformin + Sulfonylurea + SGLT2 6 . Sulfonylurea + SGLT2 7 . Metformin + SGLT2 + Insulin 8 . SGLT2 + Insulin 9 . NPH Insulin ( exception NPH insulin present premix formulation ) 10 . Rapid act insulin ( exception rapid act insulin present premix formulation ) 11 . Four ( 4 ) diabetes therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>